ARYx Therapeutics, Inc. (NASDAQ: ARYX) is an American biopharmaceutical company, headquartered in Fremont, California, focused on developing a portfolio of internally discovered product candidates.
The company uses its RetroMetabolic Drug Design technology to design molecules that retain the efficacy of original and well-established drugs but which are metabolized through a potentially safer pathway to avoid specific adverse side effects associated with these original compounds.